As pharmaceutical innovation accelerates, 2026 is poised to be a pivotal year for FDA approvals and launches. From cancer and autoimmune diseases treatments to breakthrough therapies for obesity management, the pipeline reflects both scientific advancement and shifting priorities in healthcare.
For plan sponsors, brokers, and healthcare stakeholders, understanding what’s ahead is critical to anticipating cost trends, utilization changes, and patient access challenges.
| Drug Name | Date / Release Date | Generic Name | Indication |
| Cipro HC | 11/24/2025 | Ciprofloxacin Hydrochloride; Hydrocortisone | Otitis externa |
| Mavenclad (tablet) | 11/26/2025 | Cladribine | Relapsing multiple sclerosis |
| Fycompa (oral suspension) | 12/15/2025 | Perampanel | Partial-onset and generalized tonic-clonic seizures |
| Rayos | 12/17/2025 | Prednisone | Inflammatory and autoimmune disorders |
| Edarbi | 2026–2027 | Azilsartan Medoxomil | Hypertension |
| Briviact (injection, oral solution, tablet) | 02/2026 | Brivaracetam | Partial-onset seizures |
| Nucynta (50 mg, 75mg, 100 mg) | 1Q 2026 | Tapentadol Hydrochloride | Moderate to severe pain |
| Qvar 40 and 80 | 1Q 2026 | Beclomethasone Dipropionate | Asthma maintenance therapy |
| Jentadueto XR | 1H 2026 | Linagliptin; Metformin Hydrochloride | Type 2 diabetes mellitus |
| Aplenzin (174 mg, 348 mg, 522mg) | 2026 | Bupropion Hydrobromide | Major depressive disorder |
| Atrovent HFA | 2026 | Ipratropium Bromide | COPD / bronchospasm |
| Bosulif (tablet) | 2026 | Bosutinib Monohydrate | Chronic myelogenous leukemia |
| Bryhali | 2026 | Halobetasol Propionate | Plaque psoriasis |
| Byvalson | 2026 | Nebivolol; Valsartan | Hypertension |
| Natazia | 2026 | Dienogest; Estradiol Valerate | Abnormal uterine bleeding |
| Promacta (100 mg) | 2026 | Eltrombopag Olamine | Thrombocytopenia |
| Qbrelis | 2026 | Lisinopril | Hypertension |
| Sernivo | 2026 | Betamethasone Dipropionate | Plaque psoriasis |
| Simbrinza | 2026 | Brimonidine Tartrate; Brinzolamide | Open-angle glaucoma |
| Tyvaso | 2026 | Treprostinil | Pulmonary arterial hypertension |
| Velphoro | 2026 | Ferric Oxyhydroxide | Hyperphosphatemia (CKD) |
| Yonsa | 2026 | Abiraterone Acetate | Metastatic prostate cancer |
| ZTlido (1.8%) | 2026 | Lidocaine | Postherpetic neuralgia |
| Arymo ER | 2026–2027 | Morphine Sulfate | Severe chronic pain |
| Bonjesta | 2026–2027 | Doxylamine Succinate; Pyridoxine HCl | Nausea and vomiting of pregnancy |
| Envarsus XR | 2026–2027 | Tacrolimus | Transplant rejection prophylaxis |
| Firmagon | 2026–2027 | Degarelix Acetate | Advanced prostate cancer |
| Jublia | 2026–2027 | Efinaconazole | Onychomycosis |
| Osphena | 2026–2027 | Ospemifene | Dyspareunia due to menopause |
| Rydapt (capsule) | 2026–2027 | Midostaurin | Acute myeloid leukemia |
| Tirosint-Sol | 2026–2027 | Levothyroxine Sodium | Hypothyroidism |
Expected New Brand Approvals 2025-2027
| Drug Name | Approval / PDUFA Date | Generic Name | Indication |
| Recarbrio | 12/09/2025 | Cilastatin Sodium; Imipenem; Relebactam | Ventilator-associated pneumonia; cIAI; cUTI |
| Lerochol | 12/12/2025 | Lerodalcibep | Heterozygous familial hypercholesterolemia (HeFH) |
| Exdensur | 12/16/2025 | Depemokimab | Eosinophilic asthma |
| Jascayd | 12/19/2025 | Nerandomilast | Interstitial lung disease |
| Wegovy (tablet) | 12/22/2025 | Semaglutide | Obesity |
| Ebvallo | 01/10/2026 | Tabelecleucel | Post-transplant lymphoproliferative disorder (PTLD) |
| Cerezyme | 01/13/2026 | Imiglucerase | Gaucher disease, Type 3 |
| Cutx-101 | 01/14/2026 | Copper Histidinate | Menkes disease |
| Brimochol PF | 01/28/2026 | Brimonidine Tartrate; Carbachol | Presbyopia |
| Anaphylm | 01/31/2026 | Dibutepinephrine | Anaphylactic reactions |
| Joenja (tablet) | 01/31/2026 | Leniolisib Phosphate | Activated PI3K-delta syndrome (APDS) |
| Yescarta | 02/2026 | Axicabtagene Ciloleucel | Primary CNS lymphoma (PCNSL) |
| Wegovy (injection, 7.2 mg) | 1Q 2026 | Semaglutide | Obesity |
| Azd9833 | 1H 2026 | Camizestrant | Hormone receptor–positive breast cancer |
| Bitopertin | 1H 2026 | Bitopertin | X-linked protoporphyria; EPP |
| Hepcludex | 1H 2026 | Bulevirtide | Hepatitis D |
| Ly3502970 Eli Lily | 1H 2026 | Orforglipron | Obesity |
| Pdp-716 | 1H 2026 | Brimonidine Tartrate | Open-angle glaucoma / ocular hypertension |
| Renazorb | 1H 2026 | Oxylanthanum Carbonate | Hyperphosphatemia in CKD |
| Tecvayli | 1H 2026 | Teclistamab | Multiple myeloma |
| Tzield | 1H 2026 | Teplizumab | Delay of type 1 diabetes |
This year is set to bring meaningful therapeutic advancements—but with them comes increased pressure on plan design and cost management. Staying informed on emerging FDA approvals and launches will be key to navigating what’s next.
Source:
IPD Analytics FDA approval and generic launch trackers; FDA approval data through December 2025.